Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Good morning and welcome to Novavax Fourth Quarter ... Phase 1/2 trials combining our COVID-19 vaccine with their market leading flu product, Fluzone High-Dose and Flublok. And both combination ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

The US-developed NOVAVAX vaccine against COVID-19 has been approved Monday ... of age or older and it must be administered in two doses, 21 days apart. It can be stored, handled, and distributed ...

In all Novavax said it expects to have capacity to produce two billion doses of the protein-based vaccine by next year. The study has two main goals – the first occurrence of confirmed COVID-19 ...

NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705 ...

Marathon Holdings (MARA) shares gain after reporting record-high revenue driven by ... from direct commercialization of its COVID-19 vaccine. (Reuters) -Novavax on Thursday posted a narrower ...

Novavax recorded $50 million in product sales, down 80% year over year. The downside was due to lower sales of the company’s protein-based COVID-19 vaccine (also its sole marketed product).